A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)

Trial Profile

A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Tucatinib (Primary) ; Trastuzumab emtansine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 12 Sep 2017 Results of a pooled analysis comparing PFS and the site of relapse in patients with or without brain metastases from two phase I trials (ONT-380-004 and ONT-380-005; n=77) presented at the 42nd European Society for Medical Oncology Congress
    • 06 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
    • 06 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top